Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting

Novartis Pres. Ninomiya (center) Makes Deep Bow at Tokyo Press Conference Novartis Pharma temporarily detailed its chronic myeloid leukemia (CML) treatment Tasigna (nilotinib) using the interim research findings of a clinical trial involving the drug, in which its employees were...read more